Literature DB >> 30637464

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.

Christian Daniel Fankhauser1, Travis A Gerke2, Lisa Roth1, Sophia Sander1, Nico Christian Grossmann1, Benedikt Kranzbühler1, Daniel Eberli1, Tullio Sulser1, Joerg Beyer3, Thomas Hermanns1.   

Abstract

PURPOSE: To investigate whether the use of pre-orchiectomy instead of pre-chemotherapy tumor marker (TM) levels has an impact on the International Germ Cell Consensus Classification (IGCCCG) risk group assignment in patients with metastatic germ cell tumors (GCT).
METHODS: Demographic and clinical information of all patients treated for primary metastatic testicular non-seminomatous GCT in our tertiary care academic center were extracted from medical charts. IGCCCG risk group assignment was correctly performed with pre-chemotherapy marker levels and additionally with pre-orchiectomy marker levels. Agreement between pre-chemotherapy and pre-orchiectomy risk group assignments was assessed using Cohen's kappa.
RESULTS: Our cohort consisted of 83 patients. The use of pre-orchiectomy TMs resulted in an IGCCCG risk group upstaging in 12 patients (16%, 8 patients from good to intermediate risk and 4 patients from intermediate to poor risk) and a downstaging in 1 patient (1.2%, from intermediate- to good-risk). The agreement between pre-orchiectomy and pre-chemotherapy IGCCCG risk groups resulted in a Cohen's kappa of 0.888 (p < 0.001).
CONCLUSIONS: Using pre-orchiectomy TMs can result in incorrect IGCCCG risk group assignment, which in turn can impact on the clinical management and follow-up of patients with metastatic GCT. Thus, adherence to the IGCCCG standard using pre-chemotherapy TMs levels is recommended.

Entities:  

Keywords:  Biomarkers, tumor; Prognosis; Testicular germ cell tumor

Mesh:

Substances:

Year:  2019        PMID: 30637464     DOI: 10.1007/s00432-019-02844-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance.

Authors:  João Lobo; Ana Laura Costa; Mariana Cantante; Rita Guimarães; Paula Lopes; Luís Antunes; Isaac Braga; Jorge Oliveira; Mattia Pelizzola; Rui Henrique; Carmen Jerónimo
Journal:  J Transl Med       Date:  2019-03-12       Impact factor: 5.531

2.  XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality.

Authors:  João Lobo; Sandra P Nunes; Ad J M Gillis; Daniela Barros-Silva; Vera Miranda-Gonçalves; Annette van den Berg; Mariana Cantante; Rita Guimarães; Rui Henrique; Carmen Jerónimo; Leendert H J Looijenga
Journal:  Cancers (Basel)       Date:  2019-09-17       Impact factor: 6.639

3.  Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.

Authors:  João Lobo; Ângelo Rodrigues; Rita Guimarães; Mariana Cantante; Paula Lopes; Joaquina Maurício; Jorge Oliveira; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2019-10-11       Impact factor: 6.639

4.  Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.

Authors:  João Lobo; Vera Constâncio; Catarina Guimarães-Teixeira; Pedro Leite-Silva; Vera Miranda-Gonçalves; José Pedro Sequeira; Laura Pistoni; Rita Guimarães; Mariana Cantante; Isaac Braga; Joaquina Maurício; Leendert H J Looijenga; Rui Henrique; Carmen Jerónimo
Journal:  Mol Oncol       Date:  2021-03-02       Impact factor: 6.603

5.  [Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging].

Authors:  Pia Paffenholz; Tim Nestler; Yasmine Maatoug; Melanie von Brandenstein; Barbara Köditz; David Pfister; Axel Heidenreich
Journal:  Urologe A       Date:  2021-01-11       Impact factor: 0.639

6.  The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).

Authors:  Christoph Seidel; Gedske Daugaard; Tim Nestler; Alexey Tryakin; Mikhail Fedyanin; Christian Daniel Fankhauser; Thomas Hermanns; Jorge Aparicio; Julia Heinzelbecker; Pia Paffenholz; Axel Heidenreich; Ugo De Giorgi; Richard Cathomas; Anja Lorch; Anna Fingerhut; Fabian Gayer; Felix Bremmer; Patrizia Giannatempo; Andrea Necchi; Daniele Raggi; Gaetano Aurilio; Chiara Casadei; Marcus Hentrich; Ben Tran; Klaus-Peter Dieckmann; Margarido Brito; Christian Ruf; Alessandro Mazzocca; Bruno Vincenzi; Olof Stahl; Carsten Bokemeyer; Christoph Oing
Journal:  World J Urol       Date:  2021-03-08       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.